comparemela.com
Home
Live Updates
FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic A
FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic A
FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic Adenocarcinoma
The FDA has approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the frontline treatment of metastatic pancreatic adenocarcinoma.
Related Keywords
,
Nalirifox ,
Irinotecan Liposome Injection ,
Onivyde ,
Metastatic Pancreatic Adenocarcinoma ,
Pdac ,